Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | JAK1 | P23458 | 8/20 | 0.59 |
| ▸ | ACHE | P22303 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 6/20 | 0.52 |
| ▸ | TYK2 | P29597 | 5/20 | 0.52 |
| ▸ | JAK3 | P52333 | 5/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27966037 | 0.86 | GRIN2B (0.59) | CYP1A2CYP2D6HIF1AJAK1MEN1 | |
| SCHEMBL1120768 | 0.83 | JAK2 (0.62) | CYP1A2CYP2D6HIF1AJAK1JAK2 | |
| SCHEMBL1376865 | 0.83 | JAK2 (0.62) | CYP1A2CYP2D6HIF1AJAK1JAK2 | |
| SCHEMBL12561873 | 0.82 | JAK2 (0.61) | JAK1JAK2CSF1R | |
| SCHEMBL20183411 | 0.80 | JAK1 (0.60) | CYP2D6JAK1MEN1JAK2TYK2 | |
| SCHEMBL20183409 | 0.80 | JAK1 (0.60) | CYP2D6JAK1MEN1JAK2TYK2 | |
| SCHEMBL5359231 | 0.80 | GRIN2B (0.63) | CYP2D6JAK1JAK2TYK2JAK3 | |
| SCHEMBL3534327 | 0.79 | JAK2 (0.70) | JAK1JAK2JAK3 | |
| SCHEMBL3534101 | 0.79 | JAK1 (0.66) | JAK1JAK2JAK3 | |
| SCHEMBL3542175 | 0.78 | JAK1 (0.68) | JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | CYP1A2 1602/4885CYP2D6 1867/4885HIF1A 3237/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | CYP1A2 1601/4885CYP2D6 1996/4885HIF1A 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.